However, when patients with diabetes develop COVID-19, treatment with SGLT2 inhibitors or GLP1 RAs should deserve careful attention on a case-by-case basis, dependent on their own clinical presentation and concurrent comorbidities. The gene discussed is SLC5A2; the disease is diabetes mellitus.